Aspreva Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, England

September 12, 2006

VICTORIA, Sept. 13 /CNW/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall, President and Co-Founder, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, England.

The 20 minute presentation will be followed by a 20 minute Question and Answer period and will take place on Thursday, September 21st at 10:00 am BST at the Merrill Lynch Financial Centre.

A live audio web cast of the presentation will be available to all interested parties through a link posted on Aspreva's website at www.aspreva.com in the Investors section.

About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva's strategy allows its partners to maintain core brand focus while extending the benefits of their medicines to a broader patient population. Aspreva is listed on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".


For further information: Sage Baker, VP, Investor Relations & Corporate Communications, Aspreva Pharmaceuticals, (250) 744-2488 ext. 84270, sbaker@aspreva.com